Sinil Pharmaceutical Co., Ltd. (KOSDAQ:012790)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,040.00
-10.00 (-0.17%)
At close: Sep 11, 2026

Sinil Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
6,4197,53114,30113,64112,1576,679
Depreciation & Amortization
6,2315,9915,6075,3614,4324,536
Loss (Gain) From Sale of Assets
216.5924.33-3.72641.55-221.3-14
Asset Writedown & Restructuring Costs
-108.28-108.28-31792.08-14.5
Loss (Gain) From Sale of Investments
-10.95-1.3426.81532.61373.44-115.48
Provision & Write-off of Bad Debts
68.534.21797.59446.86409.12160.62
Other Operating Activities
1,182-191.63,161-408.832,9032,102
Change in Accounts Receivable
-2,600452855.221,095-3,247161.49
Change in Inventory
-2,634-147.89-369.61-2,304-3,487236.85
Change in Accounts Payable
1,515-446.88-113.72-1,2711,8401,210
Change in Other Net Operating Assets
597.6-1,548-1,541-2,587-1,563-3,779
Operating Cash Flow
10,89511,58922,68915,15413,68811,163
Operating Cash Flow Growth
-28.61%-48.92%49.72%10.72%22.61%0.92%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-2,897-3,145-10,362-13,604-10,351-3,343
Sale of Property, Plant & Equipment
23.82-74.92122.76316.6145.68
Sale (Purchase) of Intangibles
-663.26-767.92-94.64-57-27.5-285.65
Investment in Securities
-1,279-971.61-13,2682,510-4,880-3,103
Other Investing Activities
3032176.53-291.662.27-95
Investing Cash Flow
-4,736-4,803-23,473-11,319-14,880-6,665

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
---22,578--
Total Debt Issued
---22,578--
Short-Term Debt Repaid
----22,578--
Long-Term Debt Repaid
--149.49-147.23-154.09-133.75-127.98
Total Debt Repaid
-142.55-149.49-147.23-22,732-133.75-127.98
Net Debt Issued (Repaid)
-142.55-149.49-147.23-154.09-133.75-127.98
Repurchase of Common Stock
----73.39-104.49-168.43
Dividends Paid
-2,196-2,196-1,965-1,112-1,081-1,051
Other Financing Activities
36222-2492--0
Financing Cash Flow
-2,303-2,124-2,136-1,248-1,319-1,347

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
263.487.544.83-11.37114.9425.44
Miscellaneous Cash Flow Adjustments
----0--
Net Cash Flow
4,1204,670-2,8762,576-2,3963,176

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
7,9978,44412,3271,5513,3367,820
Free Cash Flow Growth
5.12%-31.50%694.85%-53.52%-57.34%245.93%
Free Cash Flow Margin
9.21%10.48%13.78%1.74%4.17%12.66%
Free Cash Flow Per Share
-730.461066.39134.13299.94695.63
Levered Free Cash Flow
5,5845,3098,588-2,857148.738,141
Unlevered Free Cash Flow
5,5945,3218,605-2,840152.528,147

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
15.8519.7126.9726.136.059.72
Cash Income Tax Paid
1,3573,145468.263,081772.841,113
Change in Working Capital
-3,102-1,691-1,169-5,067-6,457-2,170